The clinical trials market in Thailand is expected to reach a projected revenue of US$ 2,120.5 million by 2033. A compound annual growth rate of 8.8% is expected of Thailand clinical trials market from 2026 to 2033.
The Thailand clinical trials market generated a revenue of USD 1,100.3 million in 2025 and is expected to reach USD 2,120.5 million by 2033.
The Thailand market is expected to grow at a CAGR of 8.8% from 2026 to 2033.
In terms of segment, phase iii was the largest revenue generating phase in 2025.
Phase I is the most lucrative phase segment registering the fastest growth during the forecast period.
Clinical trials market data book summary
Market revenue in 2025
USD 1,100.3 million
Market revenue in 2033
USD 2,120.5 million
Growth rate
8.8% (CAGR from 2026 to 2033)
Largest segment
Phase iii
Fastest growing segment
Phase I
Historical data
2021 - 2024
Base year
2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
Phase II, Phase III, Phase IV, Phase I
Key market players worldwide
Thermo Fisher Scientific Inc, Icon PLC, Charles River Laboratories International Inc, IQVIA Holdings Inc, Syneos Health, SGS AG, PAREXEL, Wuxi AppTec Co Ltd, Labcorp Holdings Inc, Eli Lilly and Co, Novo Nordisk A/S ADR, Pfizer Inc, Caidya
Other key industry trends
In terms of revenue, Thailand accounted for 1.2% of the global clinical trials market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Asia Pacific, China clinical trials market is projected to lead the regional market in terms of revenue in 2033.
Australia is the fastest growing regional market in Asia Pacific and is projected to reach USD 3,973.7 million by 2033.
Thailand’s clinical trials market is driven by a flexible regulatory process to conduct clinical trials. The rising interest of many multinational pharmaceutical companies to expand in the country due to lowcost base is anticipated to drive the market.
For instance, several large companies in Thailand have increased their overall investment, with companies boosting their outsourcing and collaborative efforts. Such factors are contributing to market growth.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Clinical Trials Market Outlook will help companies and investors design strategic landscapes.
Phase Iii was the largest segment with a revenue share of 57.24% in 2025.
Horizon Databook has segmented the Thailand clinical trials market based on phase ii, phase iii, phase iv, phase i covering the revenue growth of each sub-segment from 2021 to 2033.
Thailand’s clinical trials market is driven by a flexible regulatory process to conduct clinical trials. The rising interest of many multinational pharmaceutical companies to expand in the country due to lowcost base is anticipated to drive the market.
For instance, several large companies in Thailand have increased their overall investment, with companies boosting their outsourcing and collaborative efforts. Such factors are contributing to market growth.
Thailand Clinical Trials Market Phase Outlook (Revenue, USD Million , 2021-2033)
Phase I
Phase II
Phase III
Phase IV
Thailand Clinical Trials Market Study Design Outlook (Revenue, USD Million , 2021-2033)
Interventional Trials
Observational Trials
Expanded Access Trials
Thailand Clinical Trials Market Indication Outlook (Revenue, USD Million , 2021-2033)
Autoimmune/Inflammation
Pain management
Oncology
CNS conditions
Diabetes
Obesity
Cardiovascular
Others
Thailand Clinical Trials Market Service Type Outlook (Revenue, USD Million , 2021-2033)
Protocol Designing
Site Identification
Patient Recruitment
Laboratory Services
Analytical Testing Services
Clinical Trial Data Management Services
Others
Thailand Clinical Trials Market Sponser Outlook (Revenue, USD Million , 2021-2033)
Pharmaceutical & Biopharmaceutical Companies
Medical Device Companies
Others
Reasons to subscribe to Clinical Trials Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Clinical Trials Market Outlook databook
Our clientele includes a mix of Clinical Trials Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Thailand Clinical Trials Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Thailand Clinical Trials Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.